Cerus Corporation (CERS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $400.88M
Last updated: Nov 17, 2026 at 11:04 AM ET
Cerus Corporation (CERS) Earnings: Report Dates and Results
Cerus (CERS) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Cerus reported EPS of $0.00, above the -$0.01 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CERS has an expected report date of Mar 1, 2027.
CERS Earnings Call
The latest CERS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CERS beat 17, missed 12 and matched 11. Revenue for the quarter ended Sep 30, 2026 was $57.71M, up 9.5% from $52.70M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.00 | -$0.01 | -$0.02 - -$0.01 | +73.00% | Beat | N/A | 2 | 0 up, 0 down | Nov 2, 2026 | $57.71M |
| Jun 30, 2026 | -$0.01 | -$0.01 | -$0.01 - -$0.01 | 0.00% | In line | N/A | 2 | 0 up, 1 down | Jul 30, 2026 | $57.44M |
| Mar 31, 2026 | -$0.01 | -$0.04 | -$0.04 - -$0.03 | +75.00% | Beat | N/A | 2 | 0 up, 1 down | Apr 30, 2026 | $53.66M |
| Dec 31, 2025 | -$0.01 | -$0.01 | -$0.01 - $0.00 | -33.33% | Miss | N/A | 2 | 0 up, 0 down | Mar 2, 2026 | $64.58M |
| Sep 30, 2025 | $0.00 | -$0.02 | -$0.03 - -$0.02 | +99.50% | Beat | N/A | 2 | 0 up, 1 down | Nov 6, 2025 | $52.70M |
| Jun 30, 2025 | -$0.03 | -$0.02 | -$0.03 - -$0.01 | -50.00% | Miss | N/A | 2 | 1 up, 1 down | Aug 5, 2025 | $52.45M |
| Mar 31, 2025 | -$0.04 | -$0.05 | -$0.07 - -$0.03 | +20.00% | Beat | N/A | 2 | N/A | May 1, 2025 | $43.24M |
| Dec 31, 2024 | -$0.01 | -$0.01 | -$0.02 - -$0.01 | 0.00% | In line | N/A | 4 | 0 up, 0 down | Feb 20, 2025 | $56.75M |
| Sep 30, 2024 | -$0.02 | -$0.03 | -$0.03 - -$0.03 | +33.33% | Beat | N/A | 6 | 0 up, 0 down | Oct 30, 2024 | $50.66M |
| Jun 30, 2024 | -$0.03 | -$0.04 | -$0.06 - -$0.03 | +25.00% | Beat | N/A | 6 | 0 up, 0 down | Aug 1, 2024 | $50.52M |
| Mar 31, 2024 | -$0.05 | -$0.04 | -$0.07 - -$0.04 | -25.00% | Miss | N/A | 6 | 0 up, 0 down | May 2, 2024 | $43.40M |
| Dec 31, 2023 | -$0.01 | -$0.02 | -$0.03 - -$0.01 | +50.00% | Beat | N/A | 5 | 0 up, 0 down | Mar 5, 2024 | $53.34M |
| Sep 30, 2023 | -$0.03 | -$0.05 | -$0.06 - -$0.05 | +40.00% | Beat | N/A | 4 | 0 up, 0 down | Nov 2, 2023 | $47.25M |
| Jun 30, 2023 | -$0.06 | -$0.06 | -$0.07 - -$0.04 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Aug 2, 2023 | $47.73M |
| Mar 31, 2023 | -$0.09 | -$0.07 | -$0.09 - -$0.05 | -28.57% | Miss | N/A | 4 | 0 up, 0 down | May 4, 2023 | $38.48M |
| Dec 31, 2022 | -$0.08 | -$0.05 | -$0.06 - -$0.04 | -60.00% | Miss | N/A | 4 | 0 up, 0 down | Feb 28, 2023 | $51.32M |
| Sep 30, 2022 | -$0.05 | -$0.05 | -$0.07 - -$0.04 | 0.00% | In line | N/A | 5 | 1 up, 0 down | Nov 3, 2022 | $46.34M |
| Jun 30, 2022 | -$0.06 | -$0.06 | -$0.08 - -$0.06 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Aug 4, 2022 | $47.63M |
| Mar 31, 2022 | -$0.07 | -$0.08 | -$0.10 - -$0.06 | +12.50% | Beat | N/A | 5 | 0 up, 0 down | May 5, 2022 | $43.02M |
| Dec 31, 2021 | -$0.05 | -$0.08 | -$0.08 - -$0.07 | +37.50% | Beat | N/A | 5 | 0 up, 0 down | Feb 22, 2022 | $50.09M |
| Sep 30, 2021 | -$0.07 | -$0.10 | -$0.10 - -$0.08 | +30.00% | Beat | N/A | 5 | 0 up, 0 down | Nov 2, 2021 | $42.10M |
| Jun 30, 2021 | -$0.09 | -$0.09 | -$0.10 - -$0.09 | 0.00% | In line | N/A | 4 | N/A | Aug 3, 2021 | $37.76M |
| Mar 31, 2021 | -$0.10 | -$0.09 | -$0.11 - -$0.08 | -11.11% | Miss | N/A | 5 | N/A | May 4, 2021 | $29.57M |
| Dec 31, 2020 | -$0.09 | -$0.09 | -$0.10 - -$0.08 | 0.00% | In line | N/A | 5 | N/A | Feb 25, 2021 | $33.59M |
| Sep 30, 2020 | -$0.08 | -$0.10 | -$0.12 - -$0.09 | +20.00% | Beat | N/A | 5 | N/A | Oct 29, 2020 | $29.19M |
| Jun 30, 2020 | -$0.09 | -$0.10 | -$0.12 - -$0.10 | +10.00% | Beat | N/A | 4 | N/A | Aug 4, 2020 | $26.83M |
| Mar 31, 2020 | -$0.10 | -$0.10 | -$0.13 - -$0.08 | 0.00% | In line | N/A | 5 | N/A | May 5, 2020 | $24.64M |
| Dec 31, 2019 | -$0.12 | -$0.12 | -$0.13 - -$0.11 | 0.00% | In line | N/A | 4 | N/A | Feb 20, 2020 | $26.49M |
| Sep 30, 2019 | -$0.13 | -$0.12 | -$0.12 - -$0.10 | -8.33% | Miss | N/A | 6 | N/A | Oct 30, 2019 | $22.85M |
| Jun 30, 2019 | -$0.13 | -$0.12 | -$0.12 - -$0.09 | -8.33% | Miss | N/A | 4 | N/A | Aug 1, 2019 | $22.48M |
| Mar 31, 2019 | -$0.14 | -$0.11 | -$0.12 - -$0.09 | -27.27% | Miss | N/A | 5 | N/A | May 7, 2019 | $21.96M |
| Dec 31, 2018 | -$0.12 | -$0.11 | -$0.11 - -$0.10 | -9.09% | Miss | N/A | 5 | N/A | Feb 26, 2019 | $20.24M |
| Sep 30, 2018 | -$0.11 | -$0.10 | -$0.11 - -$0.09 | -10.00% | Miss | N/A | 5 | N/A | Nov 1, 2018 | $19.33M |
| Jun 30, 2018 | -$0.10 | -$0.11 | -$0.13 - -$0.10 | +9.09% | Beat | N/A | 5 | N/A | Aug 2, 2018 | $19.47M |
| Mar 31, 2018 | -$0.11 | -$0.11 | -$0.13 - -$0.10 | 0.00% | In line | N/A | 5 | N/A | May 8, 2018 | $17.02M |
| Dec 31, 2017 | -$0.10 | -$0.11 | -$0.15 - -$0.10 | +9.09% | Beat | N/A | 5 | N/A | Mar 8, 2018 | $22.57M |
| Sep 30, 2017 | -$0.12 | -$0.16 | -$0.16 - -$0.14 | +25.00% | Beat | N/A | 3 | N/A | Nov 2, 2017 | $10.80M |
| Jun 30, 2017 | -$0.16 | -$0.16 | -$0.17 - -$0.14 | 0.00% | In line | N/A | 3 | N/A | Aug 3, 2017 | $9.53M |
| Mar 31, 2017 | -$0.18 | -$0.16 | N/A | -12.50% | Miss | N/A | N/A | N/A | May 3, 2017 | $8.43M |
| Dec 31, 2016 | -$0.13 | -$0.15 | N/A | +13.33% | Beat | N/A | N/A | N/A | Mar 7, 2017 | $12.22M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.08, after -$0.11 the year before. It was -$0.62 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.08 | N/A |
| Dec 31, 2024 | -$0.11 | N/A |
| Dec 31, 2023 | -$0.19 | N/A |
| Dec 31, 2022 | -$0.26 | N/A |
| Dec 31, 2021 | -$0.31 | N/A |
| Dec 31, 2020 | -$0.36 | N/A |
| Dec 31, 2019 | -$0.52 | N/A |
| Dec 31, 2018 | -$0.44 | N/A |
| Dec 31, 2017 | -$0.56 | N/A |
| Dec 31, 2016 | -$0.62 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,335 | 8 | |
| 2026Q2 | Jun 30, 2026 | 4,310 | 5 | |
| 2026Q1 | Mar 31, 2026 | 5,681 | 8 | |
| 2025Q4 | Dec 31, 2025 | 4,241 | 7 | |
| 2025Q3 | Sep 30, 2025 | 4,492 | 7 | |
| 2025Q2 | Jun 30, 2025 | 3,911 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,826 | 10 | |
| 2024Q4 | Dec 31, 2024 | 5,539 | 10 |
2026Q3 Earnings Call
Opening remarks
Timothy J. Lee Head of Investor Relations Thank you, and good afternoon. I would like to thank everyone for joining us today. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.cerus.com. With me on the call are Vivek K. Jayaraman, Cerus' president and chief executive officer; Kevin D. Green, Cerus' Chief Financial Officer; and Dr. Nina Mufti, Cerus' Senior Vice President, Research and Development. Cerus issued two press releases this afternoon: one announcing our financial results for the third quarter ended September 30, 2026, and describing the company's recent business highlights; the other announcing top-line results from our Phase III REDeS study. You can access copies of both announcements on the company's website at www.cerus.com. I would like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts and are forward-looking statements. These include statements regarding financial outlook and performance, our business strategy and priorities, expected growth and market opportunities, clinical and regulatory activities, product launches and expansion, and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that can cause actual performance and results to differ materially. Please refer to the forward-looking statements slide accompanying today's webcast, today's press releases, and risk factors in our Form 10-Q for the quarter ended September 30, 2026, which we will file shortly, for important factors that can cause actual results to differ materially. We undertake no duty or obligation to update our forward-looking statements. On today's call, we will also be discussing non-GAAP financial measures, including non-GAAP adjusted EBITDA. These non-GAAP measures should be considered as a supplement to, and not a replacement for, measures presented in accordance with GAAP. For a reconciliation of non-GAAP financial measures to the most comparable GAAP financial measures, to the extent reasonably available, please refer to today's press release and the slide presentation available on our website. We will begin today with Vivek providing a business update and corporate highlights, followed by Kevin to review our financial results and expectations for the rest of 2026, and lastly, closing remarks from Vivek. And now it is my pleasure to introduce Vivek K. Jayaraman, Cerus' president and chief executive officer.
Vivek K. Jayaraman President and Chief Executive Officer Thank you, Timothy, and good afternoon, everyone. We appreciate you joining us today. At Cerus, our mission is clear: to expand patient access to safer blood and establish INTERCEPT as the standard of care for transfused blood components globally. Our third-quarter kit sales represent nearly 800,000 doses of transfusable blood.
Frequently Asked Questions About CERS
When is Cerus's next earnings date?
Cerus's next earnings report is expected for Mar 1, 2027.
Did CERS beat earnings estimates last quarter?
Yes. Cerus reported EPS of $0.00 for the quarter ended Sep 30, 2026, above the -$0.01 estimate, a 73.00% surprise.
What EPS do analysts expect from CERS next quarter?
The consensus EPS estimate for Cerus for the quarter ending Dec 31, 2026 is -$0.01 from 6 analysts, with estimates from -$0.01 to $0.00.
How often does CERS beat earnings estimates?
Cerus beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +23.02%.
CERS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts